Tech Company Financing Transactions
Organogenesis Funding Round
Eastward Capital Partners participated in a $20 million venture round for Organogenesis. The financing round was announced by the company on 5/23/2017.
Transaction Overview
Company Name
Announced On
5/23/2017
Transaction Type
Debt
Amount
$20,000,000
Round
Undisclosed
Investors
Eastward Capital Partners (Timothy O'Loughlin)
Proceeds Purpose
We are excited to partner with Organogenesis to provide the capital to support their growth plans.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
85 Dan Rd.
Canton, MA 02021
USA
Canton, MA 02021
USA
Phone
Website
Email Address
Overview
Having pioneered the field, Organogenesis Inc. is a commercial leader in regenerative medicine, focused in the areas of bio-active wound healing and soft tissue regeneration. The company was originally founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gary Gillheeney
Chief Operating Officer
Patrick Bilbo
Vice President
Antonio Montecalvo
Vice President
Zorina Pitkin
VP - General Counsel
Lori Freedman
VP - Human Resources
Thomas Pearl
VP - Manufacturing
Christopher O'Reilly
Browse more venture capital transactions:
Prev: 5/23/2017: LumaStream venture capital transaction
Next: 5/24/2017: ViaCyte venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs